Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

ACEIs linked to increased risk of lung cancer

An observational study of almost one million people suggests a link between angiotensin converting enzyme inhibitors and an increased risk of lung cancer.

X-ray lung cancer

Source: Shutterstock.com

Compared with angiotensin receptor blockers, angiotensin converting enzyme inhibitors were associated with a 14% increased risk of lung cancer

Angiotensin converting enzyme inhibitors (ACEIs) are associated with an increased risk of lung cancer compared with angiotensin receptor blockers (ARBs), results of a study published in The BMJ show (24 October 2018)[1].

The research used general practice data on 992,061 people in the UK who began taking antihypertensive medicine between 1995 and the end of 2015. Follow-up was between 1 and 20 years (mean 6.4 years), during which time there were 7,952 cases of lung cancer.

Compared with ARBs, ACEIs were associated with a 14% increased risk of lung cancer (1.2 vs. 1.6 per 1,000 person-years). This risk increased with duration of use, rising to 22% at five years and 31% at ten years.

The researchers explained that biological evidence has suggested that ACEIs could increase the risk of lung cancer because they lead to an accumulation of bradykinin, which has been reported to stimulate growth of lung cancer, and substance P, which has been associated with tumour proliferation and angiogenesis, in the lung. However, they said that there is a lack of clear evidence from observational studies.

They concluded: “Although the magnitudes of the observed estimates are modest, these small relative effects could translate into large absolute numbers of patients at risk for lung cancer, so these findings need to be replicated in other settings.”

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205825

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £43.00Buy now
  • MCQs in Pharmacy Practice

    MCQs in Pharmacy Practice

    A study aid with 800 MCQs. Assess your knowledge, analytical skills, and ability to apply this knowledge base in clinical practice.

    £25.00Buy now
  • Facilitating Learning in Healthcare

    Facilitating Learning in Healthcare

    Assist learning in healthcare effectively with this practical guide. Designed specifically for people from non-teaching backgrounds.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.